Literature DB >> 12795745

Emerging role of calprotectin in gastroenterology.

Andrew Poullis1, Russell Foster, Michael A Mendall, Magne K Fagerhol.   

Abstract

Calprotectin is a calcium and zinc binding protein of the S100 family derived predominantly from neutrophils and monocytes. It is detectable in body fluids and tissue samples and is emerging as a valuable marker in the diagnosis, and the monitoring and determining of the prognosis of commonly encountered gastroenterological conditions. Fecal calprotectin, in particular, has for a long time been regarded as a promising marker of gastrointestinal pathology and has now been established as a routine test in Norway and at several centers in the UK. Copyright 2003 Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12795745     DOI: 10.1046/j.1440-1746.2003.03014.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  31 in total

Review 1.  Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease.

Authors:  Anet A Soubières; Andrew Poullis
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

2.  Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy.

Authors:  Takayuki Yamamoto; Manabu Shiraki; Takuya Bamba; Satoru Umegae; Koichi Matsumoto
Journal:  Int J Colorectal Dis       Date:  2013-12-17       Impact factor: 2.571

3.  Soluble ST2: a new and promising activity marker in ulcerative colitis.

Authors:  David Díaz-Jiménez; Lucía E Núñez; Caroll J Beltrán; Enzo Candia; Cristóbal Suazo; Manuel Alvarez-Lobos; María-Julieta González; Marcela A Hermoso; Rodrigo Quera
Journal:  World J Gastroenterol       Date:  2011-05-07       Impact factor: 5.742

4.  Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn's Disease.

Authors:  Gilles Boschetti; Marc'harid Laidet; Driffa Moussata; Carmen Stefanescu; Xavier Roblin; Gildas Phelip; Eddy Cotte; Guillaume Passot; Yves Francois; Jocelyne Drai; Emilie Del Tedesco; Yoram Bouhnik; Bernard Flourie; Stephane Nancey
Journal:  Am J Gastroenterol       Date:  2015-03-17       Impact factor: 10.864

5.  Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease.

Authors:  Renata D'Incà; Elisabetta Dal Pont; Vincenza Di Leo; Antonio Ferronato; Walter Fries; Maria Grazia Vettorato; Diego Martines; Giacomo Carlo Sturniolo
Journal:  Int J Colorectal Dis       Date:  2006-07-13       Impact factor: 2.571

6.  Increased faecal calprotectin predicts recurrence of colonic diverticulitis.

Authors:  Antonio Tursi; Walter Elisei; Marcello Picchio; Giovanni Brandimarte
Journal:  Int J Colorectal Dis       Date:  2014-05-07       Impact factor: 2.571

7.  Crohn's disease patients have more IgG-binding fecal bacteria than controls.

Authors:  Hermie J M Harmsen; Simon D Pouwels; Anouk Funke; Nicolaas A Bos; Gerard Dijkstra
Journal:  Clin Vaccine Immunol       Date:  2012-02-15

Review 8.  Oral fluid-based biomarkers of alveolar bone loss in periodontitis.

Authors:  Janet S Kinney; Christoph A Ramseier; William V Giannobile
Journal:  Ann N Y Acad Sci       Date:  2007-03       Impact factor: 5.691

9.  Myeloperoxidase-dependent lipid peroxidation promotes the oxidative modification of cytosolic proteins in phagocytic neutrophils.

Authors:  Rachel P Wilkie-Grantham; Nicholas J Magon; D Tim Harwood; Anthony J Kettle; Margreet C Vissers; Christine C Winterbourn; Mark B Hampton
Journal:  J Biol Chem       Date:  2015-02-19       Impact factor: 5.157

10.  Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis.

Authors:  Jun-Ying Xiang; Qin Ouyang; Guo-Dong Li; Nan-Ping Xiao
Journal:  World J Gastroenterol       Date:  2008-01-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.